3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Thyroid Neoplasms
2
Brain Neoplasms
2
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Interventions
Trastuzumab
77
Capecitabine
59
Cyclophosphamide
54
Paclitaxel
51
Docetaxel
49
Letrozole
44
Fulvestrant
43
Lapatinib
34
Doxorubicin
31
Carboplatin
31
Vinorelbine
30
Bevacizumab
29
Anastrozole
28
pembrolizumab
25
exemestane
24
Tamoxifen
23
Gemcitabine
22
Radiotherapy
21
Albumin-Bound Paclitaxel
19
Everolimus
17
Taxes
16
Epirubicin
15
Ado-Trastuzumab Emtansine
13
130-nm albumin-bound paclitaxel
13
pertuzumab
12
palbociclib
12
liposomal doxorubicin
11
Magnetic Resonance Spectroscopy
11
Filgrastim
11
Cisplatin
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Breast Neoplasms
×
alectinib
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts